The efficacy of VIIBRYD was established in two 8-week, placebo-controlled trials in adult patients with MDD.
The mechanism of the antidepressant effect of VIIBRYD is thought to be related to its enhancement of serotonergic activity in the central nervous system (CNS) through selective inhibition of serotonin reuptake.
The results of previous study demonstrated that VIIBRYD was superior to placebo and improves depressive symptoms as measured by the mean change from baseline (95% confidence interval) to week 8 in the montgomery-asberg depression rating scale (MADRS).